|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Instituto de Biologia y Medicina Experimental-CONICET, Buenos Aires, Argentina
* To whom correspondence should be addressed. E-mail: dbecu{at}dna.uba.ar.
Recent evidence shows that re-expression and upregulation of Angiotensin II (Ang II) type 2 (AT2) receptor in adult tissues occur during pathological conditions such as tissue hyperplasia, inflammation and remodeling. In particular, expression of functional AT2 receptors in the pituitary, their physiological significance and regulation has not been described. In this study, we demonstrate that chronic in vivo estrogen treatment which induces pituitary hyperplasia enhances local AT2 expression (measured by Western blot and RT- PCR) concomitantly with downregulation of Ang II type 1 (AT1) receptors. In vivo progesterone (P4) treatment of estrogen-induced pituitary hyperplasia did not modify either the Ang II receptor subtype expression pattern or the octapeptide-induced and AT1-mediated calcium signaling. Nevertheless, an unexpected potentiation of the Ang II prolactin releasing effect was observed in this group, and this response was sensitive to both AT1 and AT2 receptor antagonists. These data are the first to document that Ang II can act at the pituitary level through the AT2 receptor subtype and that estrogens display a differential regulation of AT1 and AT2 receptors at this level.
This article has been cited by other articles:
![]() |
Kai Chen, D. C. Merrill, and J. C. Rose The Importance of Angiotensin II Subtype Receptors for Blood Pressure Control During Mouse Pregnancy Reproductive Sciences, October 1, 2007; 14(7): 694 - 704. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |